Patients with advanced kidney cancer who received an experimental vaccine after their tumors were removed were still ...

Blockbuster Keytruda makes up nearly half of Merck’s sales. That’s becoming an issue.

Merck's combination of a wide lineup of high-margin drugs and a pipeline of new drugs should ensure strong returns on invested capital over the long term. Further, following the divestment of the ...

Merck swung to a fourth-quarter profit as sales grew and even exceeded Wall Street's estimates, boosted in part by the performance of top asset Keytruda. The drug company logged net income of $3.74 ...

Merck & Co. and Eisai reported mixed results from a late-stage study of the cancer drugs Keytruda and Lenvima in patients with certain types of gastroesophageal cancer. Merck and Eisai on Friday ...

The trial was studying U.S. drugmaker Merck's blockbuster immunotherapy Keytruda and Eisai's Lenvima, in combination with chemotherapy, as a first-line treatment for patients with a type of ...

Prostate cancer has proved an elusive target for cancer immunotherapies, and Merck & Co's checkpoint inhibitor Keytruda is the latest to fall short in the disease in a phase 3 trial. Merck has ...

Keytruda (pembrolizumab) is an immunotherapy drug used to treat certain types of lung cancer by helping the immune system detect and combat cancer cells. Currently, it is offered to patients with a ...

Despite the lowered price target from $136 to $119 due to risks related to Keytruda’s loss-of-exclusivity and Medicare price caps, Graybosch remains optimistic about Merck’s ability to shift ...

Merck CEO Rob Davis told CNBC's Jim Cramer that there's more to the pharmaceutical giant than its lucrative cancer drug, Keytruda, and he described other ventures in its portfolio. "Keytruda has ...